Flow Cytometry Market: Local Enterprises Have Great Prospects
The production capacity of florfenicol raw materials is limited or there may be an oversold rebound.
After the Spring Festival, as the veterinary raw material drug market rose to a high level, the market began to weaken, and the veterinary raw material drug market showed a downward trend. However, with the arrival of the peak season for traditional demand, the veterinary raw material drug market may rebound.
Among the Veterinary Raw Materials monitored by the China Veterinary Drug and Feed Trading Center, the market prices of many varieties have dropped significantly.

However, with the advent of summer, the market trend of veterinary drug raw materials may usher in a wave of rebound, and the prices of some products may enter an upward channel.
First, the veterinary raw material drug market is about to enter the peak season of traditional demand, and the downstream market demand is gradually increasing. The rigid demand restricts the downside of the raw material drug market.
Second, the cumulative increase in external factors, environmental protection, security inspections and other factors may cause some companies to restrict or even stop production, and the supply of veterinary raw materials in the veterinary drug market has tightened. The upstream raw material plant of FLORFENICOL has been suspended due to environmental protection. Recently, the news has been released. The florfenicol plant has a high price mentality, and the market has responded positively and focused attention.
Third, the summer high temperature maintenance season is coming. Historical data shows that the high temperature maintenance of mainstream manufacturers will have a greater impact on product market prices.
Fourth, the early-stage demand has weakened, shipments are not smooth, intermediate channels have reduced prices for shipments, withdrawn funds, some channels have been oversold, and inventories have dropped to low levels. Once market demand improves, full replenishment of the industry chain will be triggered, which may be promoted by then Product prices are rising rapidly.
Looking for chemical products? Let suppliers reach out to you!
2026-07-12
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Moderna to Cut 10 Percent of Staff as COVID Vaccine Sales Plunge Stock Drops 4 Percent
-
Bayer Sets Aside $1.37 Billion for Roundup Lawsuits Raises 2025 Sales Forecast to €48 Billion
-
Trump Pressures 17 Pharma CEOs to Match US Drug Prices with Global Lows September 29 Deadline Set
-
JB Pharma Q1 Net Profit Surges 14 Percent to ₹202 Crore Revenue Hits ₹1094 Crore with 30 Percent EBITDA Margin
-
Mounjaro Reduces Heart Events by 8 Percent More Than Trulicity in 13,000-Patient Diabetes Trial
-
Sun Pharma Halts US Expansion Amid 25 Percent Tariff Threat Net Profit Drops 20 Percent
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Wall Street Predicts New Obesity Pills Will Be Priced Near $1000 Like Wegovy and Zepbound Supply and Competition Pressures Mount
Recommend Reading
-
Glenmark Targets 10–15 Percent CAGR in India by Shifting to High-Margin Drugs AbbVie Deal and New Launches Boost Outlook
-
Haryana’s Drug Crackdown Gets Massive Public Support State Launches Podcast to Boost Community Involvement
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
-
Tinci Materials Calls Off 2.65 Billion Yuan Project as Electrolyte Giant Shifts Strategy
-
Eastern Shenghong Projects First-Half Profit of 5 Billion Yuan – A Collective Turnaround for the Four Major Private Refiners? Is the Chemical Sector Rebounding?
-
September Isobutanol Prices Fluctuate and Decline
-
The Golden September Lacks Luster, Phthalic Anhydride Prices Stabilize at the Bottom in September
-
Costs Decline as September DOP Prices Fluctuate and Fall